Cellular Origins and Fresenius Kabi have completed the first phase of a CGT manufacturing collaboration announced in October 2024.
CAMBRIDGE, England & STEVENAGE, England--(BUSINESS WIRE)--Cellular Origins, a TTP Company focused on enabling scalable, cost-effective, and efficient manufacture of cell and gene therapies (CGTs), and ...
Researchers have completed the first phase of a collaboration integrating robotic cell processing with automated ...
Cellular Origins and Fresenius Kabi, an operating company of Fresenius, announce today they have signed a development agreement that leverages each company’s expertise in cell and gene therapies (CGTs ...
Cellular Origins, a TTP Company focused on enabling scalable, cost-effective, and efficient manufacture of cell and gene therapies (CGTs), and the Cell and Gene Therapy Catapult (CGT Catapult), an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results